The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells
© The Author(s). 2016
Received: 23 August 2016
Accepted: 6 October 2016
Published: 22 October 2016
Embelin is a potent dual inhibitor of 5-lipoxigenase (5-LOX) and microsomal prostaglandin E2 synthase (mPGES)-1 that suppresses proliferation of human glioma cells and induces apoptosis by inhibiting XIAP and NF-κB signaling pathway. Synthetic structural modification yielded the derivative 3-((decahydronaphthalen-6-yl)methyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione (RF-Id), an embelin constrained analogue, with improved efficiency against 5-LOX in human neutrophils and anti-inflammatory activity in vivo. Taking into account that lipoxygenase (LOX) metabolites, from arachidonic acid and linoleic acid, have been implicated in tumor progression, here, we determined whether RF-Id was able to hinder glioblastoma (GBM) cancer cell growth and the related mechanisms.
U87MG and LN229 cells were plated in 96-wells and treated with increasing concentrations of RF-Id. Cell viability was evaluated by MTT assay. The effects of the compounds on cell cycle, apoptosis, oxidative stress and autophagy were assessed by flow cytometry (FACS). The mode of action was confirmed by Taqman apoptosis array and evaluating caspase cascade and NFκB pathway by western blotting technique.
Here, we found that RF-Id induced a stronger inhibition of GBM cell growth than treatment with embelin. Flow cytometry analysis showed that RF-Id induced about 30 % apoptosis and a slight increase of autophagy after 72 h on U87-MG cells. Moreover, the compound induced an increase in the percentage of cells in G2 and S phase that was paralleled by an increase of p21 and p27 expression but no significant changes of the mitochondrial membrane potential; array analysis showed a significant upregulation of CASP8 and a downregulation of IAP family and NFκB genes in cells treated with RF-Id. RF-Id induced a significant cleavage of caspases 8, 9, 3 and 7, blocked c-IAP2/XIAP interaction by inducing XIAP degradation and inhibited NFκB pathway.
RF-Id induced a caspase-dependent apoptosis in GBM cells by inhibiting IAP family proteins and NFκB pathway and represents a promising lead compound for designing a new class of anti-cancer drugs with multiple targets.
KeywordsApoptosis Glioblastoma IAPs NFκB RF-Id
Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults. Combination of radiotherapy and temozolomide (TMZ) represents the gold-standard first-line treatment for GBM [1, 2]. In recent phase II trials, also nitrosoureas such as fotemustine (FTM) have shown mild activity for recurrent GBM [3, 4]. The blood–brain barrier (BBB) is the most important limiting factor for the development of new drugs and drug delivery for the central nervous system (CNS) . In this context, we showed that the newly developed transferrin (Tf)-targeted self-assembling nanoparticles (NPs) incorporating zoledronic acid (ZOL) allowed the successfully use of ZOL in the treatment of GBM, potentiating its in vitro and in vivo antitumor activity on GBM through the acquisition of ability to cross the BBB .
Despite the aggressive first-line therapy and the recent results with surgery, radiation therapy and adjuvant chemotherapy, tumors invariably recur and median survival is 15 months . Further progress towards a cure for malignant gliomas will require a greater understanding of the underlying mechanisms driving the growth and resistance to therapy of these tumors.
In this framework, it is well established that many cancers derive from sites of chronic inflammation; the tumor environment, which is orchestrated by the interplay between inflammatory cells, tumor cells, and other tumor-associated host cells, is an essential member in the tumorigenic progression. Cancer and inflammation are intimately linked due to specific oxidative processes in the tumor microenvironment.
In this context, the pro-inflammatory microenviroment in various human brain tumors is characterized by high expression of 5-Lipoxygenases (5-LOX) , a versatile class of oxidative enzymes involved in arachidonic acid metabolism, that promote the proliferation of glioma cells [9–12]. In addition, is well recognized that the inhibitors of 5-LOX can activate Caspase-3 inducing glioma cell apoptosis, suggesting that 5-LOX can participate in the survival of glioma cells . In this context NDGA, a natural 5-LOX inhibitor, and its methylated derivative, terameprocol, exhibited anticancer activity; moreover, terameprocol is a global transcription inhibitor that affects cell division, apoptosis, drug resistance, hypoxia responsive genes, and radiation resistance in hypoxia. Previous research indicated terameprocol as a drug that could be safely combined with radiation in newly diagnosed high-grade glioma .
Starting from these considerations, as cancer is a multifactor disease, there is great interest in the development of new compounds able to target multiple intracellular components.
Our group have been interested for a long time in the synthesis and the biological evaluation of anti-cancer and anti-inflammatory agents including quinone-based compounds [15–26]. Within the context of our investigations towards the synthesis of quinone derivatives with prospects for therapeutic use, we recently studied the natural compound embelin, a potent dual inhibitor  of 5-lipoxigenase (5-LOX) and microsomal prostaglandin E2 synthase (mPGES)-1 able to suppress proliferation of human glioma cells and to induce apoptosis by inhibiting XIAP and NF-κB signaling pathway [27–29].
Moreover, we have previously discovered (RF-Id), an embelin constrained analogue, with improved efficiency against 5-LOX in human neutrophils and anti-inflammatory activity in vivo [15, 19], and the aim of the present study was to determine the precise cellular mechanisms of the new 5-LOX inhibitor RF-Id and verify its intrinsic inhibition of XIAP function.
All reagents were analytical grade and purchased from Sigma Aldrich (Milano, Italy). RPMI, DMEM were purchased from Life Technologies (Carlsbad, CA) supplemented with 10 % FBS (fetal bovine serum), 1 % penicillin, streptomycin and L-glutamine from Lonza Group Ltd (Svizzera). The rabbit antibodies raised against α − tubulin, caspase-3, detecting endogenous levels of full length caspase-3 (35 kDa) and the large fragment of caspase-3 resulting from cleavage (17 kDa); caspase-8, detecting endogenous level of total caspase-8 (57 kDa), including the p10 subnit of the activated protein; caspase-9, detecting endogenous levels of full length caspase-9 (47 kDa), a large fragment (35 kDa or 17 kDa) and a small fragment (10 kDa) of caspase-9 resulting from cleavage; p21, p27, XIAP, C-IAP-2, pIKKα/β, IKKα/β, pIKBα, IKBα and p65 subunit of NFκB were purchased by Cell Signaling Technology. The rabbit antibody raised against caspase -7 detecting endogenous levels of full length caspase-7 (34 kDa) was purchased by Santa Cruz Biotechnology.
The compound RF-Id was synthesized and characterized as reported previously . RF-1d-met was prepared starting from 1,2,4,5-tetramethoxybenzene and decahydronaphthalene-2-carbaldehyde. Coupling the above aldehyde with the lithium anion of 1,2,4,5-tetramethoxybenzene (2.5 equiv of BuLi, THF) afforded compound RF-1d-met as a mixture of diastereomers in 65 % yield.
Human GBM cell lines U87MG and LN229 were provided by Dr. Carlo Leonetti (Regina Elena Cancer Institute, Rome, Italy). U87MG and LN229 cells were grown in RPMI and DMEM, respectively, supplemented with 10 % heat-inactivated fetal bovine serum, 20 mM HEPES, 100 U/mL penicillin, 100 mg/mL streptomycin, 1 % L-glutamine and 1 % sodium pyruvate. Cells were cultured at 37 °C in a 5 % CO2 −95 % air environment in a humidified incubator.
Cell proliferation assay
Cells were seeded in serum-containing media in 96-well plates at the density of 2 × 103 cells/well. After 24 h incubation at 37 °C, cells were treated with increasing concentrations of RF-Id, embelin and reference compounds (0,8–100 μM) for 24 h, 48 h and 72 h. Cell viability was assessed by adding MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] solution in phosphate-buffered saline (PBS) to a final concentration of 5 mg/mL. The plates were then incubated at 37 °C for an additional 4 h and the MTT-formazan crystals were solubilized in 1 N isopropanol/hydrochloric acid 10 % solution at 37 °C on a shaking table for 20 min. The absorbance values of the solution in each well were measured at 570 nm using a Bio-Rad 550 microplate reader (Bio-Rad Laboratories, Milan, Italy). Percentage of cell viability was calculated as the following formula (absorbance of the treated wells - absorbance of the blank control wells)/(absorbance of the negative control wells - absorbance of the blank control wells). All MTT experiments were performed in quadruplicate.
Flow cytometric analysis of cell cycle
U87MG cells were seeded in 6-well plates in a number of 2 × 105 cells per well and were treated 24 h later with the concentration inhibiting 50 % of cell growth (IC:50) of RF- Id. After 72 h of treatment, cells were washed in PBS and directly stained in a PI solution (50 μg PI in 0.1 % sodium citrate, 0.1 % NP40, pH 7.4) for 30 min at 4 °C in the dark. Flow cytometry analysis was performed using a BD Accuri™ C6 (Becton Dickinson). To evaluate cell cycle, PI fluorescence was collected as FL3 (linear scale) by the ModFIT software (Becton Dickinson). For the evaluation of intracellular DNA content, at least 20,000 events for each point were analyzed in at least three different experiments giving a SD less than 5 %.
Flow cytometric analysis of apoptosis
Apoptotic cell death was analysed by Annexin-V–FITC staining and by propidium iodide (PI) detection systems (eBioscences, Vienna, Austria). Briefly, U87MG cells were seeded in 6-well plates in a number of 2 × 105 cells per well and were treated 24 h later with Rf-Id IC:50. After 72 h of treatment cells were trypsinezed, washed twice with PBS 1X and pellets were resuspended in 200 μL Binding Buffer 1X. Then, 5 μL Annexin V-FITC were added to 195 μL cell suspension, mixed and incubated for 10 min at room temperature. Cells were washed with 200 μL Binding Buffer 1×, resuspended in 190 μL Binding buffer 1× and 10 μL Propidium Iodide (20 μg/mL) was added. The detection of viable cells, early apoptosis cells, late apoptosis cells and necrotic cells were performed by BD Accuri™ C6 (Becton Dickinson). For each sample, 2 × 104 events were acquired. Analysis was carried out by triplicate determination on at least three separate experiments.
Western blot analysis
U87MG cell lines were treated with RF-Id (IC:50) for 24 h, 48 h and 72 h or Bortezomib (500nM) for 24 h or a combination of Bortezomib and RF-Id for 24 h and 72 h, respectively at 37 °C. For cell extract preparation, cells were washed twice with ice-cold PBS, trypsinized and centrifuged for 30 min at 4 °C in 1 ml of lysis buffer (1 % Triton, 0.5 % sodium deoxycholate, 0.1 NaCl, 1 mM EDTA, pH 7.5, 10 mM Na2HPO4, pH 7.4, 10 mM PMSF, 25 mM benzamidin, 1 mM leupeptin, 0.025 units/ml aprotinin). Equal amounts of cell proteins were separated by SDS-PAGE in a sample buffer 1× (Sample Buffer 5X: Tris 10 mg/ml, SDS 30 mg/ml, b-mercaptoethanol 0.15 ml, glycerol 0.3 ml, bromophenol blue), electrotransferred to nitrocellulose membrane. Membrane were washed in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0,05 % Tween 20), and blocked with TBST supplemented with 5 % nonfat dry milk. Then, membranes were incubate with primary antibodies in TBST and 5 % nonfat dry milk, washed, and incubated with horseradish peroxidase-conjugated secondary antibodies. All primary Abs were used at a diluition of 1:1000, instead all secondary Abs were used at a diluition of 1:2000. Blots were then developed using enhanced chemiluminescence detection reagents ECL (Thermo Fisher Scientific, Rockford, IL) and exposed to x-ray film. All films were scanned by using Quantity One software (BioRad Chemi Doc).
Flow cytometric analysis of mitochondrial potential (Mitotracker Red)
Changes in mitochondrial membrane potential due to ROS generation was analyzed by flow cytometry by using Mitotracker Red CMXRos (INVITROGEN Carlsbad, California, Stati Uniti). Briefly, U87MG and LN229 cells were plated in 6-multiwell plates at the density of 2 × 105 cells/well. After treatment, cells were detached, centrifuged at 1200 g for 5 min and resuspended in PBS. Mitotracker Red probe was added at a final concentration of 100 nM. The latter does not emit fluorescence if it is not internalized in living cells. Mitotracker Red is oxidised in presence of ROS and emits a red fluorescence (FL2 channel) directly proportional to the potential of mitochondrial membrane. After the incubation with probe for 20 min at room temperature in the dark, cells were centrifuged, resuspended and analysed by BD Accuri™ C6. For each sample, 20,000 events were acquired. Analysis was carried out by triplicate determination on at least three separate experiments.
Flow cytometric analysis of autophagy
Autofagy was analyzed by flow cytometry by using monodansylcadaverine (MDC)(Sigma-Aldrich, Saint Louis, Missouri, Stati Uniti) staining. MDC is an auto-florescent agent used as a selective marker for autophagic vacuoles (AVOs) and especially autolysosomes. U87MG cells were plated in 6-multiwell plates at the density of 2 ×105 cells/well. After 72 h of treatment cells were incubated with 50 μM of MDC in PBS 1x at 37 °C for 15 min. After the incubation the cells were washed twice in PBS 1×, trypsinized and resuspended in 500 μl of PBS 1×. Analysis was performed by flow cytometric (BD Accuri™ C6). The fluorescent emissions were collected through FL1 channel. For the quantitative evaluation of MDC, BD Accuri™ C6 software (Becton Dickinson) was used to calculate MFIs. The MFIs were calculated by the formula (MFI treated/MFI control), where MFI treated is the fluorescence intensity of cells treated with the various compounds and MFI control is the fluorescence intensity of untreated and unstained cells. For each sample, 20,000 events were acquired. Analysis was carried out by triplicate determination on at least three separate experiments.
RNA extraction and Taqman Human Apoptosis Array-Real-Time-PCR
Total RNA was prepared from U87MG cells according to mirVana PARIS (Ambion) protocol. In details, cells were centrifuged at 1,500 rpm for 5 min; the pellets obtained were placed on ice and then resuspended in 300 μl of Disruption Buffer. Successively, an equal volume of Denaturing Buffer (previously set at 37 °C) was added to the pellets and they were incubated in ice for 5–10 min. Then, Phenol-chloroform was added in the tube in a volume equal to the total volume and centrifugated at 10,000 rcf for 5 min. After centrifugation, the aqueous phase was collected and a volume of absolute ethanol equal to 1.25 times that of the collected volume was added. Then 700 μL at a time were collected, applied in Filter Cartridge and centrifuged at 10,000 rcf for 5 min. 700 μL of Wash Solution 1 were added on each Filter Cartridge, followed by centrifugation at 10,000 rcf for 40 s, later two washings with 500 μl of Wash Solution 2 were performed. Finally, 50 μl of Eluition Buffer (preheated at 95 °C) were added to the Filter Cartridge, previously placed on new tubes. Then, the samples were quantized to Nanodrop (Technologies Inc., Wilmington, DE). The cDNA was obtained by using QuantiTect Reverse Transcription Kit, (Quiagen) according to the manufacturer’s instructions. PCR products for all the genes tested were assessed in triplicate wells using TaqMan pre-developed assay reagents. The arithmetic standard normalization procedures recommended by the Data Assist software for microarray data were followed. In brief, data transformation was corrected for the signal from the three endogenous controls (18S, ACTB, GAPDH). Per card (mean) normalization accounted for the variability of each card by dividing all of the measurements on each card by the value of the 50th percentile. Per gene normalization accounted for the variability between probe sets for the three reporter genes. The threshold cycle, Ct, was automatically assigned by the SDS2.2 software package (Applied Biosystems). Relative quantities (RQ) were determined using the equation RQ = 2 − ΔΔCt. All data were generated in triplicate (different TLDA plates) and expressed as the mean ± SD. Differentially expressed genes were selected from the normalized data using a procedure known as significance analysis of microarrays, as installed in the SDS2.3 software package (Applied Biosystems). Genes were considered to be significant when their average fold change (FC) was ≤ −1.5 or ≥1.5, and statistically significant when the corresponding p value was ≤0.05. Two software programs were used to analyze the data, namely SDS RQ Manager 1.2 and DataAssist v.2.2 software (Applied Biosystems).
Taqman human apoptosis array contains 93 human genes in addition to 3 endogenous controls (18S, ACTB, GAPDH). Real-time quantitative PCR was performed on a ViiA7™ Real time PCR system (Applied Biosystems, Darmstadt, Germany). Relative expression of the transcripts was measured by using ViiA7™Real-Time PCR software (Applied Biosystems, Darmstadt, Germany). Treated samples were normalized to the corresponding medium-only control.
Total protein extracts were subjected to immunoprecipitation with 2 μg of anti-XIAP or anti-cIAP2 for 24 h at 4 °C. Immune complexes were collected with 50 μl of protein A-agarose for 16 h at 4 °C. The protein A-agarose/immune complex was washed twice with cold PBS, resuspended in 20 μl of SDS-loading buffer, heated to 95 °C for 5 min and used for Western blotting analysis using anti-XIAP or anti-CIAP2.
All data are expressed as mean + SD. Statistical analysis was performed by analysis of variance (ANOVA) with Neumann-Keul’s multiple comparison test or Kolmogorov-Smirnov test where appropriate.
Effects of RF-Id on the proliferation of GBM cells
Effects of RF-Id on cell cycle modulation
In order to study the molecular mechanisms of the antiproliferative activity of RF-Id, we performed cell cycle analysis by flow cytometry. On the basis of the IC:50 values, U87MG cells resulted more sensitive to the treatment with RF-Id and were selected for subsequent experiments. Cells were treated for 72 h with RF-Id and, subsequently, were stained with propidium iodide for 1 h and analyzed by flow cytometry. For each sample, the percentage of cells in each phase of the cell cycle (G0/G1-S-G2M) was calculated.
Effects of RF-Id on apoptosis
Effects of RF-Id on mitochondrial membrane potential and autophagy
In details, cells were treated for 72 h and subsequently were stained with MDC, specific marker for autophagosomes and analyzed by flow cytometry. Analysis of the data showed that treatment with RF-Id induced a slight increase of autophagy in U87MG (120 % MFI) compared to control (100 % MFI) (Fig. 5b).
Identification of RF-Id regulated genes in apoptosis
RF-Id inhibits XIAP-cIAP2 interaction
In conclusion, RF-Id inhibited cIAP2-XIAP complex formation and IkBα degradation by leading to NFκB inhibition and caspase activation.
Several benzoquinones have been found effective in treating some forms of cancer ; in details, it has been shown that these compounds act on cells by regulating numerous mechanisms, such as apoptosis, cell cycle , interacting with human-telomeric G-quadruplex DNA  or producing reactive oxygen species (ROS) . Our group has been interested for a long time in synthesis and biological evaluation of anti-inflammatory and anti-cancer agents including quinone-based compounds [20–23]. Within the context of our investigations on quinone derivatives and on their possible therapeutic use, we recently studied the natural compound embelin and the synthetic derivative RF-Id [ 15, 19]. Previous research has demonstrated that embelin, a small inhibitor binding the Baculovirus Inhibitor of apoptosis protein Repeat (BIR) domain of the X-linked inhibitor of apoptosis protein (XIAP), suppressed proliferation of human glioma cells and induced apoptosis by inhibiting NF-κB signaling pathway. Our previous work revealed embelin as potent dual inhibitor of 5-LOX and microsomal prostaglandin E2 synthase (mPGES)-1 with IC50 values of 60 and 200 nM in cell-free assays, respectively. Moreover RF-Id, demonstrated an improved efficiency against 5-LOX in human neutrophils (IC50 = 580 nM) and in vivo anti-inflammatory activity.
The high potency on 5-LOX and the promising in vivo efficiency of synthesized compound prompted us to investigate the RF-Id antiproliferative effects in GBM tumor cell lines.
We showed that RF-Id had two major time-dependent in vitro consequences on U87-MG cells. This compound modulated cell cycle arrest and drove cells to programmed cell death by inhibiting cIAP2-XIAP complex formation and IkBα degradation and leading to NFκB pathway inactivation.
First, we found that RF-Id was more potent than its methylated derivative and embelin in inducing growth inhibition on GBM cells, in particular on U87MG cells.
In order to study the molecular mechanisms of the antiproliferative activity of RF-Id, we performed cell cycle and apoptosis analysis by flow cytometry. In details, after 72 h RF-Id induced about 30 % apoptosis and cell death was mediated by caspases and occurred through a ROS-independent mechanism. In fact, the compound induced a significant cleavage of the initiator caspases 8, 9, and of effector caspases 3 and 7 but did not induce significant alterations of the mitochondrial membrane potential associated to increased ROS production in mitochondria. Moreover, the compound induced an increase in the percentage of cells in G2 and S phase that occurred in parallel to an increase of the expression of p21 and p27. The increase of p21 and p27 could be due to a decrease of protein ubiquitination and hence, a reduced degradation rather than to an increase of gene transcription. In fact, XIAP or c-IAP2 may act as E3-ubiquitin ligases promoting the degradation of CDK inhibitors, p21 and p27 . We recorded a late increase of p21 and p27 expression after treatment with Rf-Id that could be due to a decrease of protein ubiquitination and consequently to p21 and p27 accumulation. This effect on p21 and p27 expression can be likely ascribed to RF-Id that induces XIAP degradation and c-IAP2 inhibition, blocks their ubiquitin ligases activity and reduces p21 and p27 degradation by proteosome. As shown in Additional file 1, we found a decrease of ubiquitinated form of p21 after 72 h from the beginning of Rf-Id treatment.
In addition, RF-Id induced only a slight 20%increase of autophagy that may be due to a blockage of the autophagic flow that causes an accumulation of MDC, marker of autophagosomes. The action mechanism of RF-Id was confirmed by performing apoptosis array. Data analysis, in fact, showed a significant upregulation of CASP8 and a downregulation of IAP family proteins (BIRC2, 4,5,6 and 7) and NFκB in cells treated with RF-Id for 72 h. Probably, RF-Id acts by inhibiting IAP family genes (XIAP, c-IAP1, c-IAP2) and NFκB pathway and inducing apoptosis through both intrinsic and extrinsic pathways thus, resulting in the amplification of the apoptotic signal.
Recent evidence showed that XIAP stabilizes c-IAP2 at the protein level by inhibiting its auto-ubiquitination and the increased expression of c-IAP2 enhances the phosphorylation of IκBα that favours its subsequent proteasomal degradation leading to activation of the canonical NFκB pathway [34, 35]. In fact, we hypothesized that RF-1d by inhibiting XIAP could decrease c-IAP2, but we found that c-IAP2 was indeed increased. Based on these results, we suggest that RF-Id could disrupt XIAP-cIAP2 binding by inducing XIAP ubiquitination and proteosome-mediated degradation as bortezomib blocked RF-Id-mediated XIAP degradation and increased its expression. On this light, RF-Id could bind and stabilize c-IAP2 at the protein level by displacing XIAP but inhibits its activity as caspase inhibitor by blocking BIR3 domain of c-IAP2, as a consequence we found that RF-Id activated caspases 3, 7, 8 and 9. Binding of the XIAP RING domain to c-IAP2 is a pre-requisite for stabilization of c-IAP2, even though the RING activity may be defective, suggesting that occupation of BIR domains 2 and 3 on c-IAP2 by XIAP through its RING finger guarantees the ensuing increase in c-IAP2 stability. Protein interactions occur through binding of BIR2 and BIR3 domains of c-IAP2 with the RING finger of XIAP. RF-Id probably binds BIR3 domain of c-IAP2 and stabilizes it by blocking its degradation but inhibits its caspase inhibitor activity so that the BIR-bound caspases are released and reactivated; in the same time, Rf-Id displaces XIAP that undergoes to auto-ubiquitination and is degraded via proteosome. Moreover, Rf-Id acts inhibiting c-IAP1 while c-IAP2 undergoes to a posttranscriptional regulation; it increases because its degradation is reduced. In fact, it is reported that cells from c-IAP1(-/-) mice express markedly elevated levels of c-IAP2 protein in the absence of increased c-IAP2 mRNA. Transient transfection studies with wild-type and E3-defective c-IAP1 revealed that c-IAP2 is a direct target for c-IAP1-mediated ubiquitination and subsequent degradation .
On the other hand, bortezomib antagonized the effects of RF-Id by increasing XIAP–cIAP2 complex leading to IKKα/β-mediated IKBα phosphorylation and NFκB activation as it blocked RF-Id-mediated XIAP degradation . As reported in the literature , Bortezomib downregulated cIAP2 expression, probably by a NFκB-independent mechanism. Moreover, Rf-Id mediated both apoptosis and caspase activation through degradation of XIAP, that acts as apoptosis inhibitor by binding caspases 9, 3 and 7. Bortezomib antagonized Rf-Id-mediated caspase activation as it blocked XIAP degradation making XIAP able to inhibit caspase-mediated apoptosis.
RF-Id induced apoptosis associated with modulation of cell cycle on U87MG by inducing XIAP degradation and inhibiting NFκB pathway. In conclusion, RF-Id could represent a new therapeutic strategy in GBM, due to its highly lipophilic structure, able to target multiple intracellular components.
This work was supported in part by the grant PON 03 PE_00060_07 (MIUR) Sviluppo pre-clinico di nuove terapie e di strategie innovative per la produzione di molecole ad azione farmacologica.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
RF and MC conceived, designed the study, and wrote the paper. SZ designed the experiment, analyzed and interpreted the data. CS, MS, performed the experiment CS, MDR, DI gave technical support and conceptual advice. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs. 2011;20(7):881–95.PubMedView ArticleGoogle Scholar
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, EuropeanOrganisation for Research and Treatment of Cancer Brain Tumor and RadiotherapyGroups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapyplus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedView ArticleGoogle Scholar
- De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, Tortorelli G, Leti M, Turriziani M, Aquino A, Bonmassar E, De Vecchis L, Torino F. Focus on Fotemustine. J Exp Clin Cancer Res. 2006;25(4):461–8.PubMedGoogle Scholar
- Malhaire JP, Lucas B, Simon H, Person H, Dam-Hieu P, Labat JP. Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull Cancer. 1999;86(3):289–94.PubMedGoogle Scholar
- Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol. 2006;60(3):181–93.PubMedView ArticleGoogle Scholar
- Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014;5(21):10446–59.PubMedPubMed CentralView ArticleGoogle Scholar
- Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 1998;18(2B):1303–11.PubMedGoogle Scholar
- Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M. 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol. 2009;28(6):445–52.PubMedView ArticleGoogle Scholar
- Golubic M, Prayson RA, Vargo L, Bondar J, Barnett GH. Increased expression of 5-lipoxygenase in glioblastoma multiforme. Adv Exp Med Biol. 2003;525:205–8.PubMedView ArticleGoogle Scholar
- Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ. Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology. 2006;26(2):99–106.PubMedView ArticleGoogle Scholar
- Nathoo N, Prayson RA, Bondar J, Vargo L, Arrigain S, Mascha EJ, Suh JH, Barnett GH, Golubic M. Increased expression of 5-lipoxygenase in high-grade astrocytomas. Neurosurgery. 2006;58(2):347–54.PubMedView ArticleGoogle Scholar
- Wang X, Chen Y, Zhang S, Zhang L, Liu X, Zhang L, Li X, Chen D. Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis. J Neurooncol. 2015;125(2):277–85.PubMedView ArticleGoogle Scholar
- Lim JY, Oh JH, Jung JR, Kim SM, Ryu CH, Kim HT, Jeun SS. MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells. J Neurooncol. 2010;97(3):339–46.PubMedView ArticleGoogle Scholar
- Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S. Adult Brain Tumor Consortium. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012;14(4):511–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Petronzi C, Filosa R, Peduto A, Monti MC, Margarucci L, Massa A, Ercolino SF, Bizzarro V, Parente L, Riccio R, de Caprariis P. Structure-based design, synthesis and preliminary anti-inflammatory activity of bolinaquinone analogues. Eur J Med Chem. 2011;46:488–96.PubMedView ArticleGoogle Scholar
- Filosa R, Peduto A, Aparoy A, Schaible AM, Luderer S, Krauth V, Petronzi C, Massa A, de Rosa M, Reddanna P, Werz O. Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase. Eur J Med Chem. 2013;67:269–79.PubMedView ArticleGoogle Scholar
- Petronzi C, Festa M, Peduto A, Castellano M, Marinello J, Massa A, Capasso A, Capranico G, La Gatta A, De Rosa M, Caraglia M, Filosa R. Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. J Exp Clin Cancer Res. 2013;32:24–35.PubMedPubMed CentralView ArticleGoogle Scholar
- Schaible AM, Filosa R, Traber H, Temml V, Noha SM, Peduto A, Weinigel C, Barz D, Schuster D, Werz O. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin. Biochem Pharmacol. 2013;86:476–86.PubMedView ArticleGoogle Scholar
- Schaible AM, Filosa R, Temml V, Krauth V, Matteis M, Peduto A, Bruno F, Luderer S, Roviezzo F, Di Mola A, de Rosa M, D’Agostino B, Weinigel C, Barz D, Koeberle A, Pergola C, Schuster D, Werz O. Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase. Br J Pharmacol. 2014;171:2399–412.PubMedPubMed CentralView ArticleGoogle Scholar
- Peduto A, Bruno F, Dehm F, Krauth V, de Caprariis P, Weinigel C, Barz D, Massa A, De Rosa M, Werz O, Filosa R. Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase. Eur J Med Chem. 2014;81(6):492–8.PubMedView ArticleGoogle Scholar
- Filosa R, Peduto A, Schaible AM, Krauth V, Weinigel C, Barz D, Petronzi C, Bruno F, Roviezzo F, Spaziano G, D’Agostino B, De Rosa M, Werz O. Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. Eur J Med Chem. 2015;94(2):132–9.PubMedView ArticleGoogle Scholar
- Schaible AM, Filosa R, Krauth V, Temml V, Pace S, Garscha U, Liening S, Weinigel S, Rummler S, Schieferdecker S, Nett M, Peduto A, Collarile S, Scuotto M, Roviezzo F, Spaziano G, de Rosa M, Stuppner H, Schuster D, D’Agostino B, Werz O. The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo. Biochem Pharmacol. 2016;16:30073–9.Google Scholar
- Peduto A, Krauth V, Collarile S, Dehm F, Ambruosi M, Belardo C, Guida F, Massa A, Esposito V, Maione S, de Rosa M, Werz O, Filosa R. Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition. Eur J Med Chem. 2016;108(1):466–75.PubMedView ArticleGoogle Scholar
- Peduto A, Pagano B, Petronzi C, Massa A, Esposito V, Virgilio A, Paduano F, Trapasso F, Fiorito F, Florio S, Giancola C, Galeone A, Filosa R. Design, synthesis, biophysical and biological studies of trisubstituted naphthalimides as G-quadruplex ligands. Bioorg Med Chem. 2011;19:6419–29.PubMedView ArticleGoogle Scholar
- Filosa R, Peduto A, Micco SD, de Caprariis P, Festa M, Petrella A, Capranico G, Bifulco G. Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. Bioorg Med Chem. 2009;17:13–24.PubMedView ArticleGoogle Scholar
- Peduto A, More V, de Caprariis P, Festa M, Capasso A, Piacente S, de Martino L, de Feo V, Filosa R. Synthesis and cytotoxic activity of new β-carboline derivatives. Mini-Rev Med Chem. 2011;11:486–91.PubMedView ArticleGoogle Scholar
- Wang A, Zhang B, Zhang J, Wu W, Wu W. Embelin-induced brain glioma cell apoptosis and cell cycle arrest via the mitochondrial pathway. Oncol Rep. 2013;29(6):2473–8.PubMedGoogle Scholar
- Park SY, Lim SL, Jang HJ, Lee JH, Um JY, Kim SH, Ahn KS, Lee SG. Embelin induces apoptosis in human glioma cells through inactivating NF-κB. J Pharmacol Sci. 2013;121(3):192–9.PubMedView ArticleGoogle Scholar
- Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 2009;55(6):423–30.PubMedView ArticleGoogle Scholar
- Khaw AK, Sameni S, Venkatesan S, Kalthur G, Hande MP. Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells. Mutat Res Genet Toxicol Environ Mutagen. 2015;793(11):86–95.PubMedView ArticleGoogle Scholar
- Salem AA, El Haty IA, Abdou IM, Mu Y. Interaction of human telomeric G-quadruplex DNA with thymoquinone: a possible mechanism for thymoquinone anticancer effect. Biochim Biophys Acta. 2015;1850(2):329–42.PubMedView ArticleGoogle Scholar
- Hong Y, Sengupta S, Hur W, Sim T. Identification of novel ROS inducers: quinone derivatives tethered to long hydrocarbon chains. J Med Chem. 2015;58(9):3739–50.PubMedView ArticleGoogle Scholar
- Metzger MB, Hristova VA, Weissman AM. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci. 2012;125(3):531–7.PubMedPubMed CentralView ArticleGoogle Scholar
- Yang W, Cooke M, Duckett CS, Yang X, Dorsey JF. Distinctive effects of the cellular inhibitor of apoptosis protein c-IAP2 through stabilization by XIAP in glioblastoma multiforme cells. Cell Cycle. 2014;13(6):992–1005.PubMedPubMed CentralView ArticleGoogle Scholar
- Selmi T, Alecci C, Dell’ Aquila M, Montorsi L, Martello A, Guizzetti F, Volpi N, Parenti S, Ferrari S, Salomoni P, Grande A, Zanocco-Marani T. ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly. BMC Cancer. 2015;15(5):357.PubMedPubMed CentralView ArticleGoogle Scholar
- Conze DB, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, Ashwell JD. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol. 2005;25(8):3348–56.PubMedPubMed CentralView ArticleGoogle Scholar
- Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114(5):1046–52.PubMedPubMed CentralView ArticleGoogle Scholar
- Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I. Bortezomib induces nuclear translocation of IκBα resulting in gene specific suppression of NFκB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res. 2011;9(2):183–94.PubMedPubMed CentralView ArticleGoogle Scholar